Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
14.29
-0.15 (-1.04%)
At close: Aug 5, 2025, 4:00 PM
14.29
0.00 (0.00%)
After-hours: Aug 5, 2025, 4:33 PM EDT
Orchard Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,075,690
Market Cap
2.07B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Dec 31, 2021 | 380 | 89 | 30.58% |
| Dec 31, 2020 | 291 | 30 | 11.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DNLI News
- 4 weeks ago - Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) - GlobeNewsWire
- 3 months ago - Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome - GlobeNewsWire
- 4 months ago - Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewsWire
- 4 months ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 4 months ago - Denali Therapeutics: Vast Pipeline, First Approval Up Ahead - Seeking Alpha
- 5 months ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - GlobeNewsWire
- 7 months ago - Why Is Denali Therapeutics Stock Trading Higher On Wednesday? - Benzinga